Comprehensive Stock Comparison
Compare SRx Health Solutions Inc. (SRXH) vs Eli Lilly and Company (LLY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | LLY | 32.0% revenue growth vs SRXH's 28.4% |
| Value | SRXH | Better valuation composite |
| Quality / Margins | LLY | 31.0% net margin vs SRXH's -9.4% |
| Dividends | LLY | 0.5% yield; 10-year raise streak; SRXH pays no meaningful dividend |
| Momentum (1Y) | LLY | +15.0% vs SRXH's -94.0% |
| Efficiency (ROA) | LLY | 16.0% ROA vs SRXH's -22.4%, ROIC 33.7% vs -18.1% |
Who Each Stock Is For
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
SRx Health Solutions is an integrated Canadian healthcare services provider that offers comprehensive specialty healthcare services across all ten provinces. It generates revenue primarily through its specialty pharmacy services — which include medication dispensing and patient support programs — and its health solutions segment that provides clinical services and chronic disease management. The company's competitive advantage lies in its integrated, technology-enabled platform that combines pharmacy services with clinical care, creating a patient-centric ecosystem that's difficult for traditional pharmacies to replicate.
Eli Lilly is a global pharmaceutical company that discovers, develops, and markets innovative medicines for serious diseases like diabetes, cancer, and autoimmune disorders. It generates revenue primarily from drug sales — with diabetes treatments like Trulicity and Mounjaro contributing over 50% of revenue — and from oncology and immunology products. The company's competitive advantage lies in its deep research and development capabilities, particularly in diabetes and obesity treatments where it has established a strong patent-protected portfolio.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
LLY leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). SRXH leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
LLY is the larger business by revenue, generating $59.4B annually — 499.6x SRXH's $119M. LLY is the more profitable business, keeping 31.0% of every revenue dollar as net income compared to SRXH's -9.4%.
| Metric | SRXHSRx Health Soluti… | LLYEli Lilly and Com… |
|---|---|---|
| RevenueTrailing 12 months | $119M | $59.4B |
| EBITDAEarnings before interest/tax | — | $28.6B |
| Net IncomeAfter-tax profit | — | $18.4B |
| Free Cash FlowCash after capex | — | $9.0B |
| Gross MarginGross profit ÷ Revenue | +19.9% | +83.0% |
| Operating MarginEBIT ÷ Revenue | -4.9% | +45.0% |
| Net MarginNet income ÷ Revenue | -9.4% | +31.0% |
| FCF MarginFCF ÷ Revenue | +1.3% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +53.9% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +4.8% |
Valuation Metrics
| Metric | SRXHSRx Health Soluti… | LLYEli Lilly and Com… |
|---|---|---|
| Market CapShares × price | $9M | $941.7B |
| Enterprise ValueMkt cap + debt − cash | $36M | $972.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.19x | 89.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 30.86x |
| PEG RatioP/E ÷ EPS growth rate | — | 14.62x |
| EV / EBITDAEnterprise value multiple | — | 50.45x |
| Price / SalesMarket cap ÷ Revenue | 0.10x | 20.91x |
| Price / BookPrice ÷ Book value/share | — | 66.65x |
| Price / FCFMarket cap ÷ FCF | 7.56x | 2273.08x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), LLY scores 6/9 vs SRXH's 3/9, reflecting solid financial health.
| Metric | SRXHSRx Health Soluti… | LLYEli Lilly and Com… |
|---|---|---|
| ROE (TTM)Return on equity | — | +77.2% |
| ROA (TTM)Return on assets | -22.4% | +16.0% |
| ROICReturn on invested capital | -18.1% | +33.7% |
| ROCEReturn on capital employed | -98.8% | +40.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | — | 2.36x |
| Net DebtTotal debt minus cash | $37M | $30.4B |
| Cash & Equiv.Liquid assets | $2M | $3.3B |
| Total DebtShort + long-term debt | $39M | $33.6B |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | 26.09x |
Total Returns (with DRIP)
A $10,000 investment in LLY five years ago would be worth $52,120 today (with dividends reinvested), compared to $599 for SRXH. Over the past 12 months, LLY leads with a +15.0% total return vs SRXH's -94.0%. The 3-year compound annual growth rate (CAGR) favors LLY at 50.9% vs SRXH's -60.9% — a key indicator of consistent wealth creation.
| Metric | SRXHSRx Health Soluti… | LLYEli Lilly and Com… |
|---|---|---|
| YTD ReturnYear-to-date | -47.4% | -2.4% |
| 1-Year ReturnPast 12 months | -94.0% | +15.0% |
| 3-Year ReturnCumulative with dividends | -94.0% | +243.3% |
| 5-Year ReturnCumulative with dividends | -94.0% | +421.2% |
| 10-Year ReturnCumulative with dividends | -94.0% | +1411.6% |
| CAGR (3Y)Annualised 3-year return | -60.9% | +50.9% |
Risk & Volatility
SRXH is the less volatile stock with a -1.27 beta — it tends to amplify market swings less than LLY's 0.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 92.8% from its 52-week high vs SRXH's 5.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SRXHSRx Health Soluti… | LLYEli Lilly and Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -1.27x | 0.65x |
| 52-Week HighHighest price in past year | $2.16 | $1133.95 |
| 52-Week LowLowest price in past year | $0.08 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +5.8% | +92.8% |
| RSI (14)Momentum oscillator 0–100 | 43.4 | 46.9 |
| Avg Volume (50D)Average daily shares traded | 27.2M | 2.6M |
Analyst Outlook
LLY is the only dividend payer here at 0.49% yield — a key consideration for income-focused portfolios.
| Metric | SRXHSRx Health Soluti… | LLYEli Lilly and Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1214.28 |
| # AnalystsCovering analysts | — | 44 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $5.18 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| SRx Health Solution… (SRXH) | $93M | $119M | +28.4% |
| Eli Lilly and Compa… (LLY) | $20.0B | $45.0B | +125.7% |
Eli Lilly and Company's revenue grew from $20.0B (2015) to $45.0B (2024) — a 9.5% CAGR.
Chart 2Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| SRx Health Solution… (SRXH) | -2.6% | -9.4% | -254.1% |
| Eli Lilly and Compa… (LLY) | 12.1% | 23.5% | +94.8% |
Eli Lilly and Company's net margin went from 12% (2015) to 24% (2024).
Chart 3P/E Ratio History — 7 Years
| Stock | 2018 | 2024 | Change |
|---|---|---|---|
| Eli Lilly and Compa… (LLY) | 37 | 65.9 | +78.1% |
Eli Lilly and Company has traded in a 15x–101x P/E range over 7 years; current trailing P/E is ~90x.
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| SRx Health Solution… (SRXH) | -3.48 | -0.9 | +74.1% |
| Eli Lilly and Compa… (LLY) | 2.18 | 11.71 | +437.2% |
Eli Lilly and Company's EPS grew from $2.18 (2015) to $11.71 (2024) — a 21% CAGR.
Chart 5Free Cash Flow — 5 Years
SRx Health Solutions Inc. generated $2M FCF in 2023 (-50% vs 2022). Eli Lilly and Company generated $414M FCF in 2024 (-92% vs 2021).
SRXH vs LLY: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SRXH or LLY a better buy right now?
Eli Lilly and Company (LLY) offers the better valuation at 89.9x trailing P/E (30.9x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SRXH or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.2%, compared to -94.0% for SRx Health Solutions Inc. (SRXH). A $10,000 investment in LLY five years ago would be worth approximately $52K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1412% versus SRXH's -94.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SRXH or LLY?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc. (SRXH) is the lower-risk stock at -1.27β versus Eli Lilly and Company's 0.65β — meaning LLY is approximately -151% more volatile than SRXH relative to the S&P 500.
04Which has better profit margins — SRXH or LLY?
Eli Lilly and Company (LLY) is the more profitable company, earning 23.5% net margin versus -9.4% for SRx Health Solutions Inc. — meaning it keeps 23.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus -4.9% for SRXH. At the gross margin level — before operating expenses — LLY leads at 81.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SRXH or LLY?
In this comparison, LLY (0.5% yield) pays a dividend. SRXH does not pay a meaningful dividend and should not be held primarily for income.
06Is SRXH or LLY better for a retirement portfolio?
For long-horizon retirement investors, SRx Health Solutions Inc. (SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -1.27)). Both have compounded well over 10 years (SRXH: -94.0%, LLY: +1412%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SRXH and LLY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.